




January 2012

Volume 17 · Numbers 1/2

pp. 1–96



Cover Story

The leading story of this issue of *Drug Discovery Today*, by Giovanni Bottegoni, Angelo Favia, Maurizio Recanatini and Andrea Cavalli reports on fragment-based and computational methods that might accelerate and optimize the discovery of multitarget drugs. The authors explain how computer-assisted protocols can provide invaluable insights into how to unveil compounds theoretically able to bind to more than one protein. Furthermore, several pragmatic aspects related to the use of these approaches are covered, thus offering the reader practical insights on multitarget-oriented drug discovery projects.

DRUG DISCOVERY TODAY

REVIEWS

KEYNOTE

- 10 Target–drug interactions: first principles and their application to drug discovery**

Sara Núñez, Jennifer Venhorst and Chris G. Kruse

- 23 The role of fragment-based and computational methods in polypharmacology**

Giovanni Bottegoni, Angelo D. Favia, Maurizio Recanatini and Andrea Cavalli

GENE TO SCREEN

- 35 Targeting heat shock response pathways to treat pancreatic cancer**

Yi Xia, Palma Rocchi, Juan L. Iovanna and Ling Peng

INFORMATICS

- 44 Toward *in silico* structure-based ADMET prediction in drug discovery**

Gautier Moroy, Virginie Y. Martiny, Philippe Vayer, Bruno O. Villoutreix and Maria A. Miteva

POST SCREEN

- 56 Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle**

Alleyn T. Plowright, Craig Johnstone, Jan Kihlberg, Jonas Pettersson, Graeme Robb and Richard A. Thompson

- 63 The regulatory framework of biosimilars in the European Union**

Paola Minghetti, Paolo Rocco, Francesco Cilurzo, Lucia Del Vecchio and Francesco Locatelli

- 71 Curcumin nanoformulations: a future nanomedicine for cancer**

Murali M. Yallapu, Meena Jaggi and Subhash C. Chauhan

- 81 HIV-1 proteins join the family of LIM kinase partners. New roads open up for HIV-1 treatment**

Fabrizio Manetti

- 89 The potential of incretin-based therapies in type 1 diabetes**

Chen S. Suen and Paul Burn